SHR-1210+Apatinib

DRUG2 trials

Sponsors

The First Affiliated Hospital of Zhengzhou University, Di Wu

Conditions

Acral MelanomaLocally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

The First Affiliated Hospital of Zhengzhou UniversityLocally Advanced Esophageal Squamous Cell Carcinoma

Start: 2020-04-07End: 2024-10-07Target: 80Updated: 2022-03-04

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

RecruitingNCT04331093

Di WuAcral Melanoma

Start: 2021-03-01End: 2026-12-31Target: 40Updated: 2021-05-26

Related Papers

Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial.

Journal of Clinical Oncology2024-06-011 citations

355. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL

Diseases of the Esophagus2022-09-011 citations

740 CAMRELIZUMAB IN COMBINATION WITH PREOPERATIVE CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY

Diseases of the Esophagus2021-09-015 citations

Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.

Journal of Clinical Oncology2021-05-205 citations

Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.

Journal of Clinical Oncology2021-01-2014 citations